In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss. Latest U.S.

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 diabetes lose an average of nearly 8% of their body weight after 40 weeks ...

How effective is Eli Lilly’s new weight loss pill compared to ... Secretary Robert F. Kennedy Jr. Kennedy has been a critic of GLP-1 drugs, saying people should simply eat a healthier diet. ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, ... but also the processed food and diet industries that have fueled and capitalized on the obesity ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type 2 diabetes. Previous versions were administered via injection.

Eli Lilly and Company, which already markets weight-loss and diabetes drugs that must be injected, is a step closer to introducing a once-daily pill for the same conditions.

Eli Lilly stock shot higher as its pill-form weight loss drug ... Eli Lilly said its orforglipron lowered blood sugar and body weight in patients with Type 2 diabetes, vs. a program of diet and ...

Eli Lilly's orforglipron reduced A1C and weight in type 2 diabetes, while weekly insulin efsitora matched daily insulin with fewer side effects.

But Eli Lilly says they didn’t see any signs of liver injury in the trial, unlike what happened with Pfizer’s pill. As for the only GLP-1 pill on the market, it’s called Rybelsus.